Combination treatment for advanced head and neck cancer using radiation and immunotherapy
A Safety and Efficacy Study of Intratumoral Diffusing Alpha Radiation Emitters in Recurrent Unresectable or Metastatic Head and Neck Squamous Cell Carcinoma
This study is testing a new treatment for advanced head and neck cancer that combines a special type of radiation with an immunotherapy drug to see if it helps patients with hard-to-treat tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 48 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Alpha Tau Medical LTD. Industry-sponsored |
| Drugs / interventions | Pembrolizumab, prednisone, radiation |
| Locations | 3 sites (Jerusalem and 2 other locations) |
| Trial ID | NCT05047094 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates a novel treatment approach for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma (mHNSCC) by combining Diffusing Alpha Radiation Emitters (DaRT) with the checkpoint inhibitor Pembrolizumab. The trial is designed as a prospective, open-label, single-arm study that will assess the safety and efficacy of this combination therapy. Patients will receive DaRT seeds implanted in their target lesions, which will be removed after 15-22 days, while concurrently undergoing treatment with Pembrolizumab. Disease evaluation will occur through radiological imaging every six weeks, starting 42 days after the DaRT insertion.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with pathologically confirmed recurrent unresectable or metastatic squamous cell carcinoma of the head and neck.
Not a fit: Patients with early-stage head and neck cancer or those who are not candidates for brachytherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients with advanced head and neck cancer who have limited treatment choices.
How similar studies have performed: While the combination of radiation therapy and immunotherapy is an emerging field, this specific approach using DaRT with Pembrolizumab is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pathologically confirmed, metastatic, or recurrent unresectable squamous cell carcinoma of the head and neck. 2. Ability to provide tissue sample, either from an archive or undergo another biopsy to provide a fresh sample 3. Targetable lesion must be technically amenable for the DaRT seeds implantation 4. Brachytherapy indication validated by a multidisciplinary team 5. Targetable lesion according to RECIST v1.1 6. Age ≥ 18 years old 7. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale ≤ 2 8. Subjects' life expectancy is more than 6 months 9. White Blood Count (WBC) ≥ 3500/µl, granulocyte ≥ 1500/µl 10. Platelet count ≥ 100,000/µl 11. Hemoglobin ≥ 9 g/dl 12. Calculated or measured creatinine clearance ≥ 60 cc/min 13. Aspartate Aminotransferase (AST) and Alanine Transaminase (ALT) ≤ 2.5 X Upper Limit of Normal (ULN) or ≤ 5 X ULN for subjects with liver metastases 14. International normalized ratio (INR) \<1.4 for patients not on Warfarin 15. Subjects are willing and able to sign an informed consent form 16. Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy. Exclusion Criteria: 1. Previous treatment for metastatic disease (for recurrent unresectable disease, previous treatment is allowed given that 6 months had elapsed from completion of treatment for primary disease) 2. Patients with brain metastases 3. Combined Positive Scores (CPS) \<1 4. Patients with known contraindications to radiotherapy 5. Any prior therapy with anti-PD-L1 (Programmed death-ligand), anti-PD-L2, anti-CTLA-4 (Cytotoxic T lymphocyte antigen) antibody, etc. 6. Any history of a sever hypersensitivity reaction to any monoclonal antibody. 7. Known hypersensitivity to any of the components of the DaRT. 8. Has a known history of active TB (Tuberculosis Bacillus ) 9. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. 10. Any diagnosis of immunodeficiency or current immunosuppressive therapy including \>10mg/day of prednisone within 14 days of enrollment is not permitted 11. Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months. 12. Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints. 13. Patient requires treatment which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT. 14. Has a known history of Human immunodeficiency virus (HIV) (HIV 1/2 antibodies). 15. Has known active hepatitis B (e.g., HBsAg reactive) or hepatitis C (e.g., HCV RNA \[qualitative\] is detected) 16. Pregnancy or lactation. 17. Patients must agree to use adequate contraception (abstinence, barrier method of birth control, or any other medically acceptable form of contraception) prior to study entry, for the duration of study participation and for 6 months after last dose of Pembrolizumab.
Where this trial is running
Jerusalem and 2 other locations
- Sharett institute, Hadassah University Hospital - Ein-Kerem — Jerusalem, Israel (Recruiting)
- Sheba Medical Center — Ramat Gan, Israel (Recruiting)
- Tel-Aviv Medical Center — Tel Aviv, Israel (Not_yet_recruiting)
Study contacts
- Principal investigator: Aron Popovtzer, MD — Sharett institute, Hadassah Medical Center - Ein-Kerem
- Study coordinator: Tami Granot
- Email: TamiG@alphatau.com
- Phone: +972-2-3737-212
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.